122852-69-1 | 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(4-methyl-1H-imidazol-5-yl)methyl]-, hydrochloride (1:1)

Packsize	Purity	Availability	Price	Discounted Price
25mg	≥98%	in stock	$33.00	$23.00
50mg	≥98%	in stock	$52.00	$36.00
100mg	≥98%	in stock	$78.00	$54.00
250mg	≥98%	in stock	$178.00	$125.00

Description

• Catalog Number: AA25207
• Chemical Name: 1H-Pyrido[4,3-b]indol-1-one, 2,3,4,5-tetrahydro-5-methyl-2-[(4-methyl-1H-imidazol-5-yl)methyl]-, hydrochloride (1:1)
• CAS Number: 122852-69-1
• Molecular Formula: C17H19ClN4O
• Molecular Weight: 330.8120
• MDL Number: MFCD03453647
• SMILES: O=C1N(CCc2c1c1ccccc1n2C)Cc1[nH]cnc1C.Cl

Computed Properties

• Complexity: 442
• Covalently-Bonded Unit Count: 2
• Heavy Atom Count: 23
• Hydrogen Bond Acceptor Count: 2
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 2

Literature

• Toluene exposure enhances acute and chronic formalin-induced nociception in rats: Participation of 5-HT(3) receptors.

  Neurotoxicology 20171201

• Current and emerging drug options in the treatment of diarrhea predominant irritable bowel syndrome.

  Expert opinion on pharmacotherapy 20150101

• 'Pre-cebo': an unrecognized issue in the interpretation of adequate relief during irritable bowel syndrome drug trials.

  Journal of clinical gastroenterology 20120901

• Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS.

  Alimentary pharmacology & therapeutics 20120901

• Experimental colitis alters expression of 5-HT receptors and transient receptor potential vanilloid 1 leading to visceral hypersensitivity in mice.

  Laboratory investigation; a journal of technical methods and pathology 20120501

• Evaluation of harm in the pharmacotherapy of irritable bowel syndrome.

  The American journal of medicine 20120401

• Evaluation of treatment continuation with alosetron by IBS-D severity criteria.

  Current medical research and opinion 20120301

• Quality of life in patients with irritable bowel syndrome.

  Journal of clinical gastroenterology 20110801

• The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies.

  Drug safety 20110701

• Alosetron for severe diarrhea-predominant irritable bowel syndrome: improving patient outcomes.

  Current medical research and opinion 20110301

• Peripherally acting therapies for the treatment of irritable bowel syndrome.

  Gastroenterology clinics of North America 20110301

• An electrochemical microfluidic platform for human P450 drug metabolism profiling.

  Analytical chemistry 20101215

• In silico binary classification QSAR models based on 4D-fingerprints and MOE descriptors for prediction of hERG blockage.

  Journal of chemical information and modeling 20100726

• Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences.

  The American journal of gastroenterology 20100401

• Alosetron for severe diarrhea-predominant irritable bowel syndrome: safety and efficacy in perspective.

  Expert review of gastroenterology & hepatology 20100201

• Using the incremental net benefit framework for quantitative benefit-risk analysis in regulatory decision-making--a case study of alosetron in irritable bowel syndrome.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20100101

• Quantifying women's stated benefit-risk trade-off preferences for IBS treatment outcomes.

  Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research 20100101

• Alosetron, cilansetron and tegaserod modify mesenteric but not colonic blood flow in rats.

  British journal of pharmacology 20091101

• Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis.

  The American journal of gastroenterology 20090701

• Intracolonical administration of protease-activated receptor-2 agonists produced visceral hyperalgesia by up-regulating serotonin in the colon of rats.

  European journal of pharmacology 20090315

• Pathogenesis and management of irritable bowel syndrome.

  Tropical gastroenterology : official journal of the Digestive Diseases Foundation 20090101

• Increased 5-hydroxytryptamine mediates post-inflammatory visceral hypersensitivity via the 5-hydroxytryptamine 3 receptor in rats.

  Digestive diseases and sciences 20081101

• Neural and psychological predictors of treatment response in irritable bowel syndrome patients with a 5-HT3 receptor antagonist: a pilot study.

  Alimentary pharmacology & therapeutics 20080801

• Effects of serotonin 5-HT(3) receptor antagonists on CRF-induced abnormal colonic water transport and defecation in rats.

  European journal of pharmacology 20080610

• Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials.

  Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20080501

• Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.

  Clinical therapeutics 20080501

• Clinical practice. Irritable bowel syndrome.

  The New England journal of medicine 20080417

• Balancing drug risk and benefit: toward refining the process of FDA decisions affecting patient care.

  The American journal of gastroenterology 20080401

• Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats.

  European journal of pharmacology 20071114

• A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.

  The American journal of gastroenterology 20070801

• Pharmacogenomics and serotonergic agents: research observations and potential clinical practice implications.

  Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20070801

• The metabolism of the 5HT3 antagonists ondansetron, alosetron and GR87442 I: a comparison of in vitro and in vivo metabolism and in vitro enzyme kinetics in rat, dog and human hepatocytes, microsomes and recombinant human enzymes.

  Xenobiotica; the fate of foreign compounds in biological systems 20070801

• The metabolism of the 5HT3 antagonists, ondansetron, alosetron and GR87442 II: investigation into the in vitro methods used to predict the in vivo hepatic clearance of ondansetron, alosetron and GR87442 in the rat, dog and human.

  Xenobiotica; the fate of foreign compounds in biological systems 20070801

• Dual role of 5-HT3 receptors in a rat model of delayed stress-induced visceral hyperalgesia.

  Pain 20070701

• Impact of 5-HT3 receptor blockade on colonic haemodynamic responses to ischaemia and reperfusion in the rat.

  Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20070701

• Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome.

  Journal of pharmacological sciences 20070701

• [Novel therapeutic approaches in the treatment of irritable bowel syndrome].

  Orvosi hetilap 20070520

• [Drug treatment of irritable bowel syndrome: an unmet need].

  Gastroenterologia y hepatologia 20070301

• The relationship between dosing of alosetron and discontinuation patterns reported by patients participating in a follow-up programme.

  Alimentary pharmacology & therapeutics 20070201

• Is there an experimental basis for the development of ischaemic colitis as a result of 5-HT3 antagonist treatment?

  Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20070201

• Effects of the 5-HT3 receptor antagonist, alosetron, in a rat model of somatic and visceral hyperalgesia.

  Pain 20061215

• Irritable bowel syndrome: a practical review.

  Southern medical journal 20061101

• A patient follow-up survey programme for alosetron: assessing compliance to and effectiveness of the risk management programme.

  Alimentary pharmacology & therapeutics 20060901

• [Antagonists of the type 3 serotonin receptor (5 -HT3) in IBS].

  Nihon rinsho. Japanese journal of clinical medicine 20060801

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data.

  The American journal of gastroenterology 20060501

• Alosetron: ischemic colitis and serious complications of constipation.

  The American journal of gastroenterology 20060501

• Drug withdrawals and the lessons within.

  Current opinion in drug discovery & development 20060101

• Acute hepatitis associated with alosetron (Lotronex).

  Journal of clinical gastroenterology 20050801

• Novelty stress increases fecal pellet output in mongolian gerbils: effects of several drugs.

  Journal of pharmacological sciences 20050801

• Intestinal propulsion of a solid non-deformable bolus.

  Journal of theoretical biology 20050707

• Pharmacogenomics and functional gastrointestinal disorders.

  Pharmacogenomics 20050701

• The effects of the 5-HT3 antagonist, alosetron, on brain serotonin synthesis in patients with irritable bowel syndrome.

  Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20050401

• Comparison between partial agonist (ME3412) and antagonist (alosetron) of 5-hydroxytryptamine 3 receptor on gastrointestinal function.

  Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20050401

• Characterization of the metabolites of alosetron in experimental animals and human.

  Xenobiotica; the fate of foreign compounds in biological systems 20050201

• A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS.

  The American journal of gastroenterology 20050101

• Irritable bowel syndrome. 10% to 20% of older adults have symptoms consistent with diagnosis.

  Geriatrics 20050101

• [Irritable bowel syndrome: a concise diagnostic and pharmacological therapy review].

  Revista de gastroenterologia del Peru : organo oficial de la Sociedad de Gastroenterologia del Peru 20050101

• Options for patients with irritable bowel syndrome: contrasting traditional and novel serotonergic therapies.

  Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20041201

• Long-term safety and efficacy of alosetron in women with severe diarrhea-predominant irritable bowel syndrome.

  The American journal of gastroenterology 20041101

• Delayed Gastric Emptying in Functional Dyspepsia.

  Current treatment options in gastroenterology 20040801

• Effect of alosetron on bowel urgency and global symptoms in women with severe, diarrhea-predominant irritable bowel syndrome: analysis of two controlled trials.

  Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association 20040801

• Pharmacodynamics and pharmacokinetics of oral contraceptives co-administered with alosetron (Lotronex).

  Digestive diseases and sciences 20040801

• Alosetron repeat dose pharmacokinetics, effects on enzyme activities, and influence of demographic factors.

  Alimentary pharmacology & therapeutics 20040715

• Alosetron use drops dramatically with risk management.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20040615

• Advances in pharmacological treatments of IBS.

  Journal of pediatric gastroenterology and nutrition 20040601

• Irritable bowel syndrome.

  Clinical evidence 20040601

• New drugs and dosage forms.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20040415

• Therapy for irritable bowel syndrome.

  The New England journal of medicine 20040318

• New options for soothing an irritable bowel.

  The Johns Hopkins medical letter health after 50 20040301

• Study design issues in irritable bowel syndrome.

  Alimentary pharmacology & therapeutics 20040101

• 5-HT3-receptor antagonist inhibits visceral pain differently in chemical and mechanical stimuli in rats.

  Journal of pharmacological sciences 20040101

• Reassessing the benefits and risks of alosetron: what is its place in the treatment of irritable bowel syndrome?

  Drug safety 20040101

• Advances in the management of irritable bowel syndrome.

  Current gastroenterology reports 20031201

• Platelet serotonin transporter in patients with diarrhea-predominant irritable bowel syndrome both before and after treatment with alosetron.

  The American journal of gastroenterology 20031201

• Alosetron and irritable bowel syndrome.

  Expert opinion on pharmacotherapy 20031101

• Re: Brandt et al.--An evidence-based approach to the management of irritable bowel syndrome in North America.

  The American journal of gastroenterology 20030901

• Irritable bowel syndrome: an overview of diagnosis and pharmacologic treatment.

  Cleveland Clinic journal of medicine 20030601

• Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride.

  The American journal of gastroenterology 20030501

• Regulatory role of 5-HT and muscarinic receptor antagonists on the migrating myoelectric complex in rats.

  European journal of pharmacology 20030425

• Safety, efficacy and costs of pharmacotherapy for functional gastrointestinal disorders: the case of alosetron and its implications.

  Alimentary pharmacology & therapeutics 20030401

• Bad medicine. Why data from drug companies may be hard to swallow.

  Scientific American 20030201

• Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials.

  Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society 20030201

• Alosetron for irritable bowel syndrome. Senior vice president of GlaxoSmithKline responds.

  BMJ (Clinical research ed.) 20030104

• Alosetron for irritable bowel syndrome. Risks of using alosetron are still unknown.

  BMJ (Clinical research ed.) 20030104

• Lipid-induced colonic hypersensitivity in irritable bowel syndrome: the role of 5-HT3 receptors.

  Alimentary pharmacology & therapeutics 20030101

• Alosetron (Lotronex) is back: should I use it to treat my patients with irritable bowel syndrome?

  Cleveland Clinic journal of medicine 20030101

• Irritable bowel syndrome genophenomics: correlation of serotonin-transporter polymorphisms and alosetron response.

  The pharmacogenomics journal 20030101

• Tegaserod and other serotonergic agents: what is the evidence?

  Reviews in gastroenterological disorders 20030101

• Alosetron in irritable bowel syndrome: strategies for its use in a common gastrointestinal disorder.

  Drugs 20030101

• Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome.

  The American journal of gastroenterology 20021201

• Evidence-based position statement on the management of irritable bowel syndrome in North America.

  The American journal of gastroenterology 20021101

• Systematic review on the management of irritable bowel syndrome in North America.

  The American journal of gastroenterology 20021101

• New developments in the diagnosis and treatment of irritable bowel syndrome.

  Current gastroenterology reports 20021001

• Condition-specific deactivation of brain regions by 5-HT3 receptor antagonist Alosetron.

  Gastroenterology 20021001

• FDA OK's two drugs for irritable bowel syndrome. The arsenal of IBS drugs is growing, but diagnosis is tricky.

  Health news (Waltham, Mass.) 20021001

• Alosetron for irritable bowel syndrome.

  BMJ (Clinical research ed.) 20020914

• FDA advisers warn of more deaths if drug is relaunched.

  BMJ (Clinical research ed.) 20020914

• Alosetron: a case study in regulatory capture, or a victory for patients' rights?

  BMJ (Clinical research ed.) 20020914

• From the Food and Drug Administration.

  JAMA 20020814

• Alosetron (lotronex) revisited.

  The Medical letter on drugs and therapeutics 20020805

• Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome.

  Gastroenterology 20020801

• Contemporary thoughts on the treatment of irritable bowel syndrome.

  Managed care interface 20020801

• Alosetron to return to market.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20020715

• The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients.

  Alimentary pharmacology & therapeutics 20020701

• FDA allows controversial bowel drug back on to market.

  Lancet (London, England) 20020615

• FDA advisory panels recommend Lotronex be put back on market.

  BMJ (Clinical research ed.) 20020504

• Effect of alosetron on left colonic motility in non-constipated patients with irritable bowel syndrome and healthy volunteers.

  Alimentary pharmacology & therapeutics 20020501

• Return of alosetron.

  Expert opinion on drug safety 20020501

• FDA recommends bringing controversial IBS drug back.

  Lancet (London, England) 20020427

• Sex and age differences in the pharmacokinetics of alosetron.

  British journal of clinical pharmacology 20020301

• Effects of 5-HT(3) antagonism on postprandial gastric volume and symptoms in humans.

  Alimentary pharmacology & therapeutics 20020201

• Safety concerns about alosetron.

  Archives of internal medicine 20020114

• Lotronex withdrawal.

  Archives of internal medicine 20020114

• FDA approves restricted marketing of Lotronex.

  FDA consumer 20020101

• Adverse drug reaction update.

  Adverse drug reactions and toxicological reviews 20020101

• Pharmacological treatment of irritable bowel syndrome--from concept to sales.

  The European journal of surgery. Supplement. : = Acta chirurgica. Supplement 20020101

• Serotoninergic neuroenteric modulators.

  Lancet (London, England) 20011215

• Effect of alosetron on theophylline pharmacokinetics.

  British journal of clinical pharmacology 20011101

• Effects of alosetron on spontaneous migrating motor complexes in murine small and large bowel in vitro.

  American journal of physiology. Gastrointestinal and liver physiology 20011001

• [Irritable bowel syndrome: diagnostic criteria and recent advancement of its pharmacological management].

  Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology 20011001

• Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome.

  The American journal of gastroenterology 20010901

• Gender-related differences in slowing colonic transit by a 5-HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome.

  The American journal of gastroenterology 20010901

• [Visceral sensitivity and functional bowel disorders: physiopathological role and therapeutic perspectives].

  Gastroenterologie clinique et biologique 20010901

• [Functional intestinal disorders and quality of life].

  Gastroenterologie clinique et biologique 20010901

• The FDA and The Lancet: an exchange.

  Lancet (London, England) 20010804

• The FDA and The Lancet: an exchange.

  Lancet (London, England) 20010804

• The FDA and The Lancet: an exchange.

  Lancet (London, England) 20010804

• The FDA and The Lancet: an exchange.

  Lancet (London, England) 20010804

• The FDA and The Lancet: an exchange.

  Lancet (London, England) 20010804

• A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome.

  Archives of internal medicine 20010723

• Possible mechanisms for ischemic colitis during alosetron therapy.

  Gastroenterology 20010701

• Lotronex and the FDA: a fatal erosion of integrity.

  Lancet (London, England) 20010519

• Serotonin receptor modulation in irritable bowel syndrome: one step forwards and one step backwards.

  Gut 20010501

• So what happened to alosetron?

  Journal of pediatric gastroenterology and nutrition 20010501

• [Irritable bowel syndrome as an interdisciplinary clinical challenge. Current views on its pathophysiology, diagnosis and treatment].

  Deutsche medizinische Wochenschrift (1946) 20010420

• A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia.

  Alimentary pharmacology & therapeutics 20010401

• Effect of alosetron on the pharmacokinetics of alprazolam.

  Journal of clinical pharmacology 20010401

• Effect of alosetron on the pharmacokinetics of fluoxetine.

  Journal of clinical pharmacology 20010401

• The challenge of irritable bowel syndrome: creating an alliance between patient and physician.

  Cleveland Clinic journal of medicine 20010301

• Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients.

  The American journal of gastroenterology 20010301

• Alosetron and the rapid component of delayed rectifying potassium current in cardiac cells.

  Life sciences 20010223

• Ischemic colitis during treatment with alosetron.

  Gastroenterology 20010201

• Lotronex withdrawn from market.

  Harvard women's health watch 20010201

• Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome.

  The American journal of gastroenterology 20010201

• Alosetron withdrawn from market.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20010101

• Novel medications for the irritable bowel syndrome: motility and sensation.

  Journal of pediatric gastroenterology and nutrition 20010101

• Irritable bowel syndrome. A poorly understood disorder.

  FDA consumer 20010101

• Glaxo Wellcome withdraws irritable bowel syndrome medication.

  FDA consumer 20010101

• Pharmacology and clinical experience with alosetron.

  Expert opinion on investigational drugs 20000101